ENOV
Enovis Corporation · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website enovis.com
- Employees(FY) 6800
- ISIN US1940145022
Performance
-8.1%
1W
-4.75%
1M
-4.22%
3M
-3.34%
6M
-23.03%
YTD
-21.54%
1Y
Profile
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
Technical Analysis of ENOV 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-12-17 19:00
ENOV: What does Argus have to say about ENOV?(Argus Research)
- 2024-12-10 19:00
ENOV: Lowering target price to $37.00(Argus Research)
- 2024-12-03 19:00
ENOV: Raising target price to $39.00(Argus Research)
- 2024-11-26 19:00
ENOV: Raising target price to $38.00(Argus Research)
- 2024-11-18 16:10
Enovis to Participate in Upcoming Investor Conferences(GlobeNewswire)
- 2024-11-18 03:10
Enovis to Participate in Upcoming Investor Conferences(Globenewswire)
- 2024-11-12 19:00
ENOV: Raising target price to $38.00(Argus Research)
- 2024-11-08 12:00
- 2024-11-08 09:55
- 2024-11-07 02:10
- 2024-11-07 00:58
Q3 2024 Enovis Corp Earnings Call(Thomson Reuters StreetEvents)
- 2024-11-06 07:15
- 2024-11-06 06:57
- 2024-11-06 06:17
Enovis: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-11-06 06:00
Enovis Announces Third Quarter 2024 Results(GlobeNewswire)
- 2024-11-05 19:00
ENOV: Raising target price to $36.00(Argus Research)
- 2024-11-05 17:00
Enovis Announces Third Quarter 2024 Results(Globenewswire)
- 2024-10-31 12:02
Enovis (ENOV) Underperformed Amid Investors’ Disappointment(Insider Monkey)
- 2024-10-31 04:32
- 2024-10-10 07:00
- 2024-10-09 19:00
- 2024-10-08 20:00
ENOV: Lowering target price to $34.00(Argus Research)
- 2024-10-03 15:39
- 2024-10-03 06:29
- 2024-09-09 15:50
- 2024-09-09 03:50
- 2024-09-05 08:00
- 2024-09-05 05:29
Here’s Why Enovis Corporation (ENOV) Slipped in Q2(Insider Monkey)
- 2024-09-04 20:00
- 2024-08-27 20:00
ENOV: Raising target price to $39.00(Argus Research)
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.